Metin EKİNCİ, Halil Hüseyin ÇAĞATAY, Zeliha YAZAR, SEYİT ALİ BİNGÖL, Ahmet KAPLAN

Inhibition of corneal neovascularization by subconjunctival injection of Ranibizumab and bevacizumab in rabbit cornea

Bu çalışmanın amacı; subkonjunktival olarak uygulanan ranibizumab and bevacizumabın tavşan korneasında anjiyogenezis üzerine etkilerini değerlendirmekti. Yirmi dört adet Yeni Zelanda tavşanının korneaları neovaskülarizasyon oluşturmak için gümüş nitrat ile koterize edildi. Gözler 10 ml %0.9 salin solusyonu ile yıkandı. Tüm gözlerde eşit miktarda kimyasal yanık oluşturulmasına dikkat edildi. Koterizasyon sonrası 24. saatte tavşanlar üç gruba ayrıldı: Kontrol grubuna (GC) (n=8) subkonjunktival 0.02 ml %0.9luk salin solüsyonu; Grub Ranibizumaba (GR) (n=8) subkonjunktival olarak 0.5 mg ranibizumab ve Grup Bevasizumaba (GB) (n=8) ise subkonjunktival olarak 1.25 mg bevacizumab 1. ve 7. günlerde uygulandı Topical antibiotik tedavisi sonrası, tavşan korneaları 14. günde çıkarıldı. Korneaların digital fotoğrafları alınarak yeni oluşmuş damarlar bilgisayar programı (google sketch-up programı) yardımıyla analiz edildi. Yeni oluşan damar yapılarının alanının kornea alanına oranları gruplar arasında değerlendirildi. Ranibizumab ve Bevasizumabın her ikisi de anjiyogenez inhibisyonunda %0.9 salin solüsyonuna kıyasla (P

Korneal neovaskularizasyonun subkonjonktival Ranibizumab ve bevacizumab enjeksiyonu ile tavşan korneasında inhibisyonu

The aim of this study was to evaluate the effects of subconjunctival ranibizumab and bevacizumab injection on angiogenesis in the rabbit cornea. The corneas of 24 New Zealand rabbits were cauterized with silver nitrate to induce neovascularization. The eyes were irrigated with 10 ml of 0.9% saline solution. The alkaline burns were similar in all the rabbits. At the 24 h after cauterization, the rabbits were divided into three groups of eight animals each: The first group (GC) received 0.02 ml 0.9% saline solution as a control group whereas second (GR) and third (GB) groups received 0.5 mg ranibizumab and 1.25 mg bevacizumab by subconjunctival injection, respectively, on days first and 7 after lesion. The rabbits corneas were extracted on the 14th day. Digital photographs of the corneas were obtained and the newly formed vessels were analyzed in a computerized system (google sketch-up program). The rates of these vessels were compared between the groups. Ranibizumab and bevacizumab were both effective on inhibition of angiogenesis, in comparison to 0.9% saline solution (P<0.05). Ranibizumab was found to be statistically more effective to reduce corneal neovascularization than bevacizumab (P<0.05). Bevacizumab and ranibizumab were found to be effective in inhibiting the corneal neovascularization in the rabbit cornea. Ranibizumab seemed more effective than bevacizumab on inhibiting corneal neovascularization in the rabbit cornea.

PDF

___

1. Ambati Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, Kleinman ME, Caldwell RB, Lin Q, Ogura Y, Orecchia A, Samuelson DA, Agnew DW, St Leger J, Green WR, Mahasreshti PJ, Curiel DT, Kwan D, Marsh H, Ikeda S, Leiper LJ, Collinson JM, Bogdanovich S, Khurana TS, Shibuya M, Baldwin ME, Ferrara N, Gerber HP, De Falco S, Witta J, Baffi JZ, Raisler BJ, Ambati J: Corneal avascularity is due to soluble VEGF receptor-1. Nature, 443, 993-997, 2006.
2. Chang JH, Gabison EE, Kato T, Azar DT: Corneal neovascularization. Curr Opin Ophthalmol, 12 (4): 242-249, 2001.
3. Azar DT: Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc, 104, 264-302, 2006.
4. Kato T, Kure T, Chang JH, Gabison EE, Itoh T, Itohara S, Azar DT: Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett, 508, 187-190, 2001.
5. Usui T, Yamagami S, Kishimoto S, Seiich Y, Nakayama T, Amano S: Role of macrophage migration inhibitory factor in corneal neovascularization. Invest Ophthalmol Vis Sci, 48 (8): 3545-3550, 2007.
6. Ambati BK, Anand A, Joussen AM, Kuziel WA, Adamis AP, Ambati J: Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci, 44 (2): 590-593, 2003.
7. Philipp W, Speicher L, Humpel C: Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci, 41 (9): 2514-2522, 2000.
8. Arevalo JF, Sanchez JG, Fromow-Guerra J, Wu L, Berrocal MH, Farah ME, Cardillo J, Rodríguez FJ; Pan-American Collaborative Retina Study Group (PACORES): Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12- month follow-up. Graefes Arch Clin Exp Ophthalmol, 247 (6): 735-743, 2009.
9. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A: Sub-conjunctival bevacizumab injection for corneal neovascularization. Cornea, 27 (2): 142-147, 2008.
10. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI: The effect of topical bevacizumab on corneal neovascularization. Ophthalmology, 115 (6): 33-38, 2008.
11. Uy HS, Chan PS, Ang RE: Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson Syndrome. Cornea, 27(1), 70-73, 2008
12. Doctor PP, Bhat PV, Foster CS: Subconjunctival bevacizumab for corneal neovascularization. Cornea, 27 (9): 992-995, 2008.
13. Oh JY, Kim MK, Shin MS, Lee HJ, Lee JH, Wee WR: The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas. Curr Eye Res, 34 (2): 85-91, 2009.
14. Mahoney JM, Waterbury LD: Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res, 4 (5): 531-535, 1985.
15. Rodrigues EB, Farah ME, Maia M, Penha FM, Regatieri C, Melo GB, Pinheiro MM, Zanetti CR: Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res, 28 (2): 117-144, 2009.
16. Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P; Tübingen Bevacizumab Study Group: Safety, penetration and efficacy of topically applied bevacizumab: Evaluation of eye drops in corneal neovascularization after chemical burn. Acta Ophthalmol, 86 (3): 322-328, 2008.
17. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology, 115 (6): 33-38, 2008.
18. Bachmann BO, Bock F, Wiegand SJ, Maruyama K, Dana MR, Kruse FE, Luetjen-Drecoll E, Cursiefen C: Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol, 126 (1): 71-77, 2008.
19. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol, 245 (10): 1577-1579, 2007.
20. Kahook MY, Schuman JS, Noecker RJ: Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging, 37(2): 148-150, 2006.
21. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A: Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res, 33 (1): 23-28, 2008.
22. Galor A, Yoo SH, Piccoli FV, Schmitt AJ, Chang V, Perez VL. Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery. Am J Ophthalmol, 149 (6): 926-931, 2010.
23. Bochmann F, Kaufmann C, Becht CN, Guber I, Kaiser M, Bachmann LM, Thiel MA: Influence of topical anti-VEGF (ranibizumab) on the outcome of filtration surgery for glaucoma; Study Protocol. BMC Ophthalmol. 11, 1, 2011.
24. Qazi Y, Wong G, Monson B, Stringham J, Ambati BK: Corneal transparency: Genesis, maintenance and dysfunction. Brain Res Bull, 81 (2-3): 198-210, 2010.
25. Zayit-Soudry S, Zemel E, Loewenstein A, Perlman I: Safety evaluation of repeated intravitreal injections of bevacizumab and ranibizumab in rabbit eyes. Retina. 30 (4): 671-681, 2010.
26. Lucentis: ScientificDiscussion. Availableat:www.emea.europa.eu/humandocs/Human/ EPAR/lucentis.htm. Accessed: 12 February 2009.
27. Avastin: Scientific Discussion. Avaliable at www.emea.europa.eu/humandocs Humans/EPAR/avastin avastin.htm. Accessed: 12 February 2009.
28. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM: Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol, 27 (5): 536-544, 1999.
29. Lien S, Lowman HB: Therapeutic anti-VEGF antibodies. Handb Exp Pharmacol, 181, 131-150, 2008.
30. Lynch SS, Cheng CM: Bevacizumab for neovascular ocular diseases. Ann Pharmacother, 41(4): 614-625, 2007.
31. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology, 114 (5): 855-859, 2007.
32. Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA: Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina, 27 (9): 1260-1266, 2007.
33. Christoforidis JB, Carlton MM, Knopp MV, Hinkle GH: PET/CT imaging of I-124-radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit model. Invest Ophthalmol Vis Sci. 52 (8): 5899-5903, 2011.
34. Dib E, Rodrigues EB, Maia M, Meyer CH, Penha FM, Furlani Bde A, Costa Ede P, Farah ME: Vital dyes in chromovitrectomy. Arq Bras Oftalmol, 72 (6): 845-850, 2009.
35. Klettner A, Roider J: Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: Efficiency and possible additional pathways. Invest Ophthalmol Vis Sci, 49 (10): 4523-4527, 2008.
36. Carneiro A, Falcão M, Pirraco A, Milheiro-Oliveira P, Falcão-Reis F, Soares R: Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res, 88 (3): 522-527, 2009.
37. Ekinci M, Yiğit FU, Oba ME, Çağatay HH, Hüseyinoğlu U, Yakan S, Arslan B: Inhibition of corneal neovascularization by ranibizumab (Lucentis): An experimental study in rabbit cornea. Kafkas Univ Vet Fak Derg, 17 (5): 853-857, 2011.
38. Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR: Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci. 50 (4): 1659-1665, 2009.
39. Sener E, Yuksel N, Yildiz DK, Yilmaz B, Ozdemir O, Caglar Y, Degirmenci E: The impact of subconjunctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model. Curr Eye Res, 36 (11): 1005-1013, 2011.
40. Stevenson W, Cheng SF, Dastjerdi MH, Ferrari G, Dana R: Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf, 10 (2): 67-83, 2012.
41. Dursun A, Arici MK, Dursun F, Vural Ozec A, Toker MI, Erdogan H, Topalkara A: Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model. International J Ophthalmol, 5 (4): 448-451, 2012.
42. Christoforidis J, Ricketts R, Pratt C, Pierce J, Bean S, Wells M, Zhang X, La Perle K: The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model. Clin Ophthalmol,6,61-69,2012.
43. Lu F, Adelman RA: Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefes Arch Clin Exp Ophthalmol, 247 (2): 171-177, 2009.
44. Campa C, Harding SP: Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets, 12 (2): 173-181, 2011.